Rabbit Polyclonal RS18 Antibody

+ +

•  

   
     All lanes : Anti-RS18 Antibody (Center) at  1:1000 dilution Lane 1: U-251 MG whole cell lysate Lane 2: HepG2 whole cell lysate Lane 3: THP-1 whole cell lysate Lane 4: Daudi whole cell lysate Lane 5: Mouse spleen lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 18 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Immunofluorescent analysis of 4% paraformaldehyde-fixed,  0. 1% Triton X-100 permeabilized U-2OS cells labeling RPS18 with P34602 at 1/25 dilution,  followed by Dylight® 488-conjugated goat anti-Rabbit IgG secondary antibody at 1/200 dilution (green).  Immunofluorescence image showing cytoplasm staining on U-2OS cell line. Cytoplasmic actin is detected with Dylight® 554 Phalloidin at 1/500 dilution (red). The nuclear counter stain is DAPI (blue).    

•  

   
     Overlay histogram showing U-2 OS cells stained with P34602(green line).  The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (P34602,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(1583138) at 1/200 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was rabbit IgG1 (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

The RS18 antibody is a monoclonal antibody developed to target specific epitopes associated with cellular proteins involved in disease pathways, particularly in cancer and autoimmune disorders. It was engineered using hybridoma technology, where B-cells from immunized hosts are fused with myeloma cells to produce immortalized antibody-secreting cell lines. RS18 recognizes a conserved region of a protein implicated in cell proliferation or immune regulation, though its exact antigen may vary depending on research context. Structurally, it belongs to the IgG subclass, typically IgG1 or IgG2. ensuring high affinity and stability in experimental applications.

In research, RS18 is widely utilized for techniques like Western blotting, immunohistochemistry, and flow cytometry to detect protein expression levels or localization in tissues and cell lines. Studies suggest its relevance in characterizing biomarkers for tumor progression or inflammatory responses. For instance, RS18 has been employed in preclinical models to investigate signaling pathways like NF-κB or MAPK, offering insights into therapeutic targeting. Its diagnostic potential includes distinguishing malignant from benign cells in pathological samples.

Despite its utility, RS18's clinical translation remains exploratory, with ongoing studies validating its specificity and efficacy in vivo. Challenges include cross-reactivity risks and batch variability, common to monoclonal antibodies. Current research focuses on optimizing RS18 for translational applications, such as antibody-drug conjugates or immune checkpoint modulation. Its development reflects broader efforts to bridge antibody-based research tools with therapeutic innovations in precision medicine.